Drugs / NDI-5001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07525960 | Jul 2026 → Aug 2027 expected | diabetes insipidus | Otsuka Pharmaceutical Development & Commercialization, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NDI-5001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07525960 ↗ |
| Route | Oral | “Participants receive NDI-5001, orally, once daily (QD), for 9 consecutive days starting on Day 1.” NCT07525960 ↗ |